|
gptkbp:instanceOf
|
gptkb:drug
anticonvulsant
|
|
gptkbp:approvedBy
|
gptkb:European_Union
gptkb:United_States
gptkb:FDA
2019
|
|
gptkbp:ATCCode
|
gptkb:N03AX39
|
|
gptkbp:brand
|
gptkb:Xcopri
Ontozry
|
|
gptkbp:CASNumber
|
1138245-13-2
|
|
gptkbp:chemicalFormula
|
1-(2-chlorophenyl)-2-(tetrazol-2-ylthio)ethanone
|
|
gptkbp:contraindication
|
hypersensitivity to cenobamate
|
|
gptkbp:developedBy
|
gptkb:SK_Biopharmaceuticals
|
|
gptkbp:drugClass
|
antiepileptic
|
|
gptkbp:eliminationHalfLife
|
50-60 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C10H10ClN3O2S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
cenobamate
|
|
gptkbp:interactsWith
|
gptkb:phenytoin
gptkb:carbamazepine
gptkb:lamotrigine
phenobarbital
oral contraceptives
clobazam
|
|
gptkbp:KEGGID
|
D11041
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
modulation of voltage-gated sodium channels
positive allosteric modulation of GABAA receptors
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL3989989
28536941
46209447
DB15159
|
|
gptkbp:riskFactor
|
drug reaction with eosinophilia and systemic symptoms (DRESS)
QT shortening
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
fatigue
headache
drowsiness
double vision
|
|
gptkbp:synonym
|
YKP3089
|
|
gptkbp:UNII
|
4B6X41759U
|
|
gptkbp:usedFor
|
treatment of partial-onset seizures
|
|
gptkbp:bfsParent
|
gptkb:SK_Life_Science,_Inc.
|
|
gptkbp:bfsLayer
|
7
|